Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | PPP1R15A | O75807 | 1/20 | 0.43 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | PPP1R15B | Q5SWA1 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322771 | 1.00 | PTGS2 (0.45) | PTGS2L3MBTL1PPP1R15AMELKPPP1R15B | |
| SCHEMBL29528324 | 0.81 | ALDH1A1 (0.52) | L3MBTL1HDAC1TSHRALDH1A1CYP1A2 | |
| SCHEMBL9211580 | 0.81 | ALDH1A1 (0.52) | L3MBTL1HDAC1TSHRALDH1A1CYP1A2 | |
| SCHEMBL156610 | 0.81 | ALDH1A1 (0.52) | L3MBTL1HDAC1TSHRALDH1A1CYP1A2 | |
| SCHEMBL1547373 | 0.81 | L3MBTL1 (0.46) | PTGS2L3MBTL1PPP1R15AMELKPPP1R15B | |
| SCHEMBL3686693 | 0.81 | ALDH1A1 (0.52) | L3MBTL1HDAC1TSHRALDH1A1CYP1A2 | |
| SCHEMBL19879746 | 0.80 | ALDH1A1 (0.45) | TSHRALDH1A1CYP1A2CYP3A4LMNA | |
| SCHEMBL9442667 | 0.80 | ALDH1A1 (0.45) | TSHRALDH1A1CYP1A2CYP3A4LMNA | |
| SCHEMBL19140150 | 0.80 | ALDH1A1 (0.45) | TSHRALDH1A1CYP1A2CYP3A4LMNA | |
| SCHEMBL16955979 | 0.80 | ALDH1A1 (0.37) | PTGS2TSHRALDH1A1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-2970112-B1 | PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-03-12 | — | — | EP | disclosed |
| EP-2968210-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY | BIO PHARM SOLUTIONS CO LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109939092-B | Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome | 比皮艾思药物研发有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109071424-B | Sulfamate derivative compound, preparation method and application thereof | 生物药品解决方案有限公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| WO-2012096458-A2 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012002773-A2 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-01-05 | — | — | WO | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | CPT1B, MYLK, PYGM | PTGS2 181/4885L3MBTL1 4140/4885PPP1R15A 1907/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | PTGS2 1836/4885L3MBTL1 1386/4885PPP1R15A 1553/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | PTGS2 2972/4885L3MBTL1 2446/4885PPP1R15A 105/4885 |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | CPS1, BCHE, ACHE | PTGS2 2950/4885L3MBTL1 3618/4885PPP1R15A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.